Table 2

Extent of exposure: pooled data from five phase III studies of SC golimumab in RA, PsA and AS

Placebo±MTXGolimumab 50 mg±MTXGolimumab 100 mg±MTX
Number of treated patients*63912491501
Number of SC injections (mean/median)6.6/6.022.4/22.027.5/35.0
Weeks of follow-up (mean/median)28.1/24.093.4/100.0115.1/144.6
Cumulative golimumab dose (mean/median), mgN/A1118.6/1100.02739.9/3500.0
Number (%) of patients by length of golimumab exposure
 <104 weeksN/A663 (53.1)604 (40.2)
 104 to <156 weeksN/A323 (25.9)200 (13.3)
 ≥156 weeksN/A263 (21.1)697 (46.4)
  • *Patients may appear in ≥1 treatment column.

  • AS, ankylosing spondylitis; MTX, methotrexate; N/A, not applicable; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SC, subcutaneous.